在線訂購 免費訂購熱線:021-59541103 021-60443211
聯系人:高小姐
電話:021-59541103 021-60443211
手機:13585831301
Q Q: 3004967995
Email:3004967995@qq.com
詳細地址:上海嘉定區嘉羅公路1661
化學性質:
規格 | 1mg 5mg |
CAS | 108212-75-5 |
別名 | N/A |
化學名 | N/A |
分子式 | C55H74IN3O21S4 |
分子量 | 1368.35 |
溶解度 | DMSO : ≥ 100 mg/mL (73.08 mM);H2O : < 0.1 mg/mL (insoluble) |
儲存條件 | Store at -20°C |
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
Shipping Condition | Evaluation sample solution : ship with blue ice |
產品描述:
PF-06647263 (anti-EFNA4-ADC) is generated via conjugation of hE22 lysine residues to the AcButDMH-N-Ac-calicheamicin-γ1 linker-payload with an average drug-to-antibody ratio (DAR) of 4.6. PF-06647263 elicits antigen- and concentration-dependent cytotoxicity, as exposure to PF-06647263 for 96 hours results in cell death (EC50= appr 1 ng/mL)[1]. CMC-544, consisting of a humanized CD22 Ab linked to calicheamicin, is effective in pediatric primary B-cell precursor acute lymphoblastic leukemia (BCP-ALL) cells in vitro. CMC-544 induces cell death in various ALL cell lines in a dose- and time-dependent way, with IC50 values ranging from 0.15 to 4.9 ng/mL. CMC-544 (10 ng/mL) is effective and specific in primary BCP-ALL cells[2]. In CMC-544-treated cells, the level of CD22 has decreased relative to that on G5/44-treated cells and continued to decrease[3].
An ADC comprising a humanized anti-EFNA4 monoclonal antibody conjugated to the DNA-damaging agent calicheamicin achieves sustained tumor regressions in both TNBC and ovarian cancer PDX in vivo. PF-06647263 (0.27, 0.36 mg/kg) results in significant tumor regressions in TNBC xenografts[1].
References:
[1]. Damelin M, et al. Anti-EFNA4 Calicheamicin Conjugates Effectively Target Triple-Negative Breast and Ovarian Tumor-Initiating Cells to Result in Sustained Tumor Regressions. Clin Cancer Res. 2015 Sep 15;21(18):4165-73
[2]. de Vries JF, et al. The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells. Leukemia. 2012 Feb;26(2):255-64
[3]. Takeshita A, et al. CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cells. Leukemia. 2009 Jul;23(7):1329-36.
特別提醒:
1. 本產品僅供科研使用。請勿用于醫藥、臨床診斷或治療,食品及化妝品等用途。請勿存放于普通住宅區。
2. 為了您的安全和健康,請穿好實驗服并佩戴一次性手套和口罩操作。
原創作者:上海莼試生物技術有限公司
留言注意事項:
1.遵守中華人民共和國有關法律、法規,尊重網上道德,承擔一切因您的行為而直接或間接引起的法律責任。
2.請您真實的反映產品的情況,不要捏造、誣蔑、造謠。如對產品有任何疑問,也可以留言咨詢。
3.未經本站同意,任何人不得利用本留言簿發布個人或團體的具有廣告性質的信息或類似言論。
您感興趣的產品* | |
您的單位* | |
聯系人* | |
聯系電話* | |
詳細地址* | |
常用郵箱* | |
請輸入您對我們的意見或建議* | |
驗證碼* | |
產品訂購說明:
1、報價含普票、運費。
2、常用試劑備貨充足,除對溫度要求極其嚴格的產品當天可發貨。
3、進口原裝產品要3-6周的貨期,詳細情況請咨詢客服。
4、訂貨時間為工作日每周一至周五16:00之前。
5、如需代為檢測,標本對環境溫度高,可聯系客服安排專人取樣(限省內客戶)。
6、代測免收代測費,一周出結果。
7、產品因運輸途中包裝破損請拒絕簽收,做退回。我們將在24小時之內為您補發 損壞產品。
8、如因單位財務制度原因,可申請先發貨,報賬后付款(此條款僅限醫院、學校信譽良好客戶)。
普票匯款信息
賬 戶 名:上海生物
開 戶 行:中國銀行山東省分行營業部
賬 號:2169 2341 6278